Abstract
The Feasibility And Safety Trial for its embolic protection device during transluminal intervention in coronary vessels: a European Registry (FASTER) was designed to demonstrate that (1) the Proxis embolic protection system can control anterograde flow and reverse blood flow in native coronary arteries and saphenous vein grafts; and (2) this system can capture embolic debris. Percutaneous coronary intervention on stenotic coronary lesions revolutionized treatment of coronary disease, but is associated with the risk of major adverse cardiac events.
Author
Horst Sievert, MD, Dennis W. Wahr, MD, Gerhard Schuler, MD, Joachim J. Schofer, MD, Gabor Sutsch, MD, Jim Pavliska, BS, and Marijke Skowasch, MS
Citation
The American Journal of Cardiology, 94(9): 1134-9, November 1, 2004.
